---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-25-000031"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:01:46.164807+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio Q4 net product revenue $7.2M; Feb ANKTIVA units up 67% MoM; RMAT designation granted

## Summary
- Net product revenue $7.2M in Q4 2024, up 21% QoQ from $6.0M in Q3; full-year net product revenue $14.2M.
- ANKTIVA February 2025 unit sales up 67% month-over-month from January; Jan+Feb combined exceed total Q4 2024 units.
- Permanent J-code (J9028) issued Jan 2025; FDA authorized expanded access of rBCG with over 45,000 vials available and 60+ sites activating.
- MAAs for ANKTIVA+BCG accepted by MHRA and EMA in Feb 2025; RMAT designation for ANKTIVA+PD-L1 t-haNK in pancreatic cancer.
- Net loss attributable to common stockholders narrowed to $59.2M in Q4 2024 from $233.4M in Q4 2023; cash and securities $149.8M at Dec 31.

## SEC filing metadata
- accession: 0001326110-25-000031
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000031/0001326110-25-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000031/ibrx-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-25-000031
- JSON: https://secwatch.observer/filing/0001326110-25-000031.json
- Plain text: https://secwatch.observer/filing/0001326110-25-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.